PRNAF OTC
Alterity Therapeutics Limited
1W: +0.0%
1M: +0.0%
3M: +627.3%
YTD: +6249.2%
1Y: +13233.3%
3Y: +7447.2%
5Y: +1631.6%
$0.40
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
-100.0% ▼
Gross Profit
-$115K
-102.2% ▼
Operating Income
-$28M
-94.7% ▼
Net Income
-$23M
-92.4% ▼
EPS (Diluted)
$-0.11
-15.8% ▼
EBITDA
-$28M
-93.9% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $5M | $4M | $4M | $5M | $0 |
| YoY Growth | +18.1% | -23.6% | +2.6% | +35.3% | -100.0% |
| Cost of Revenue | $54K | $102K | $214K | $128K | $115K |
| Gross Profit | $5M | $4M | $4M | $5M | -$115K |
| Gross Margin | 98.9% | 97.4% | 94.7% | 97.7% | — |
| R&D Expenses | $15M | $13M | $19M | $14M | $0 |
| SG&A Expenses | $5M | $5M | $5M | $5M | $11M |
| Operating Expenses | $20M | $18M | $23M | $20M | $28M |
| Operating Income | -$16M | -$15M | -$20M | -$15M | -$28M |
| Operating Margin | -302.5% | -373.0% | -487.7% | -268.0% | — |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$13M | -$14M | -$19M | -$12M | -$27M |
| Tax Expense | $70K | $104K | $46K | $68K | -$3M |
| Net Income | -$13M | -$14M | -$19M | -$12M | -$23M |
| Net Margin | -250.7% | -352.5% | -475.8% | -223.4% | — |
| EPS (Diluted) | $-0.01 | $-0.01 | $-0.01 | $-0.00 | $-0.11 |
| EBITDA | -$15M | -$15M | -$20M | -$15M | -$28M |
| Shares Outstanding | 2.41B | 2.43B | 3.65B | 6.40B | 210M |